Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics

Spero Therapeutics, Inc. (SPRO)

Today's Latest Price: $10.32 USD

0.11 (-1.05%)

Updated Nov 13 9:37am

Add SPRO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SPRO Stock Summary

  • SPRO's went public 2.03 years ago, making it older than only 5.11% of listed US stocks we're tracking.
  • SPRO's price/sales ratio is 12.64; that's higher than the P/S ratio of 91.75% of US stocks.
  • As for revenue growth, note that SPRO's revenue has grown 396.14% over the past 12 months; that beats the revenue growth of 98.45% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Spero Therapeutics Inc, a group of peers worth examining would be AGEN, LQDA, BLCM, AFMD, and SYBX.
  • SPRO's SEC filings can be seen here. And to visit Spero Therapeutics Inc's official web site, go to sperotherapeutics.com.
SPRO Daily Price Range
SPRO 52-Week Price Range

SPRO Stock Price Chart More Charts

SPRO Price/Volume Stats

Current price $10.32
Prev. close $10.49
Day low $10.32
Day high $10.35
50-day MA $10.91
200-day MA $11.27
52-week high $14.48
52-week low $5.52
Volume 2,870
Avg. volume 59,793
Dividend yield N/A
Market Cap 197.40M

Spero Therapeutics, Inc. (SPRO) Company Bio

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.

SPRO Latest News Stream

Event/Time News Detail
Loading, please wait...

SPRO Latest Social Stream

Loading social stream, please wait...

View Full SPRO Social Stream

SPRO Price Returns

1-mo -4.88%
3-mo 7.84%
6-mo -14.00%
1-year 21.99%
3-year N/A
5-year 510.65%
YTD 67.80%
2018 -47.66%
2017 N/A
2016 N/A
2015 0.00%
2014 -36.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6552 seconds.